Targeting BACE1 to help Alzheimer's patients
Inhibition of BACE1 for benefiting Alzheimer's patients
This project explores new ways to reduce harmful plaques in the brains of people with Alzheimer's disease by focusing on a specific enzyme in brain cells.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Connecticut Sch of Med/dnt NIH-funded |
| Lab location | 1 site (Farmington, United States) |
| Project ID | NIH-11174479 on NIH RePORTER |
What this research studies
Previous efforts to block an enzyme called BACE1 to reduce amyloid plaques in Alzheimer's disease faced challenges due to unwanted side effects on brain cells. This project is looking for safer ways to tackle Alzheimer's by focusing on BACE1 within specific brain support cells, known as glial cells. Researchers believe that by carefully targeting BACE1 in these cells, and also encouraging them to clear plaques more effectively, they can reduce the disease's impact. The goal is to better understand how BACE1 functions in these cells to develop new, safer treatment options for patients.
Who could benefit from this research
Good fit: This research is ultimately aimed at benefiting adults aged 21 and older who are living with Alzheimer's disease dementia.
Not a fit: Patients whose condition is not related to amyloid plaque buildup or BACE1 activity may not directly benefit from this specific therapeutic approach.
Why it matters
Potential benefit: If successful, this work could lead to new, safer treatments that reduce amyloid plaques and other Alzheimer's disease pathologies without the severe side effects seen in earlier approaches.
How similar studies have performed: Previous clinical trials targeting BACE1 successfully reduced amyloid plaques but were terminated due to significant side effects, highlighting the need for safer approaches like the one proposed here.
Where this research is happening
Farmington, United States
- University of Connecticut Sch of Med/dnt — Farmington, United States (Active)
Researchers
- Principal investigator: Yan, Riqiang — University of Connecticut Sch of Med/dnt
- Study coordinator: Yan, Riqiang
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.